Filing Details
- Accession Number:
- 0001203311-20-000106
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-09-11 18:25:19
- Reporting Period:
- 2020-09-09
- Accepted Time:
- 2020-09-11 18:25:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1060736 | Seattle Genetics Inc | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1361966 | B Vaughn Himes | 21823 30Th Drive Se Bothell WA 98021 | Chief Technical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-09-09 | 8,000 | $15.46 | 194,829 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-09-09 | 2,500 | $146.73 | 192,329 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-09-09 | 4,766 | $147.86 | 187,563 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-09-09 | 734 | $148.31 | 186,829 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-09-09 | 8,000 | $0.00 | 8,000 | $15.46 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,697 | 2021-08-24 | No | 4 | M | Direct |
Footnotes
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $ 146.175 to $ 147.17. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $ 147.255 to $ 148.215. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $ 148.30 to $ 148.35. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Shares vested at a rate of 25% on 8/24/12 and monthly thereafter until all the shares were fully vested on 8/24/15.
Billionaire Hedge Funds
